Journal article
Identification, preclinical profile, and clinical proof of concept of a novel palindromic orally bio-available pro-drug of miridesap
- Abstract:
-
Background and Purpose: Miridesap depletes serum amyloid P component (SAP) and forms a component of a novel approach to remove systemic amyloid deposits; low oral bioavailability necessitates parenteral administration. We sought to identify a pro-drug that preserves the pharmacological properties of miridesap while having adequate oral bioavailability and physical stability. The pharmacology of palindromic miridesap is unique; previous pro-drug efforts did not progress to ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
University Of Oxford
More from this funder
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- British Journal of Pharmacology Journal website
- Volume:
- 177
- Issue:
- 8
- Pages:
- 1853-1864
- Publication date:
- 2020-02-11
- Acceptance date:
- 2019-11-27
- DOI:
- EISSN:
-
1476-5381
- ISSN:
-
0007-1188
- Source identifiers:
-
1075888
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:1075888
- UUID:
-
uuid:025c2db0-4028-42c0-8d0a-b280cff821a4
- Local pid:
- pubs:1075888
- Deposit date:
- 2019-12-02
Terms of use
- Copyright holder:
- The British Pharmacological Society
- Copyright date:
- 2019
- Rights statement:
- © 2019 The British Pharmacological Society
- Notes:
- This is the accepted manuscript version of the article. The final version is available from Wiley at: https://doi.org/10.1111/bph.14956
If you are the owner of this record, you can report an update to it here: Report update to this record